ABCDx SA, a Swiss and Spanish based global leader in the field of brain injury diagnostics, and Vall d'Hebron Research Institute (VHIR), a top-tier Spanish research institution, have officially entered into a transformative partnership. This collaboration solidifies their co-ownership of the patent application for "markers for the diagnosis of large vessel occlusion" and grants ABCDx exclusive rights for commercialization. This strategic agreement is poised to propel ABCDx's valuation to new heights, reinforcing its position as an industry leader in medical diagnostics.

Under this agreement, VHIR grants ABCDx an exclusive license over 80% of the rights to the Research Results. ABCDx will have the exclusive rights to manufacture, introduce into the market, import, export, promote, offer for sale, and sell Products and Services based on the patent. Additionally, ABCDx is empowered to offer sublicenses, further expanding the reach of these innovative diagnostic solutions.

Experts believe that owning this critical patent with exclusive commercialization rights will make ABCDx an even more desirable entity for investment and acquisition. This unique position in the medical diagnostics landscape, particularly in large vessel occlusion detection, is expected to meet significant market demand with limited solutions available.

ABCDx specializes in leveraging AI and state-of-the-art biomarkers in healthcare diagnostics. Headquartered in Geneva and Barcelona, the company has consistently demonstrated its innovation prowess. This new partnership, combined with exclusive commercialization rights, further cements ABCDx's leadership in the industry.

This joint ownership and exclusive commercialization agreement have been strategically structured to unlock substantial economic value for both parties, with a particular emphasis on enhancing ABCDx's market valuation. According to Prof. Jean-Charles Sanchez, CEO of ABCDx, "This collaborative effort not only fortifies our R&D capabilities but serves as a critical value driver for our stakeholders. It’s a leap forward in our long-term strategy and enhances ABCDx’s attractiveness for both institutional investors and potential acquirers."